Advertisement

Pathologie pp 177-193 | Cite as

Plasmazellneoplasien

  • Falko Fend
Chapter

Zusammenfassung

Plasmazellneoplasien zählen zu den häufigsten hämatologischen Tumoren und Indikationen einer Knochenmarkbiopsie. Die in der WHO Klassifikation gelisteten Entitäten unterscheiden sich in ihrem morphologischen, immunhistochemischen und genetischen Profil und in ihren prognostischen Parametern. Die monoklonale Gammopathie unklarer Signifikanz, die große Gruppe des multiplen Myeloms und dessen Sonderformen, das seltene solitäre Plasmozytom des Knochens, das extramedulläre solitäre Plasmozytom und das osteosklerotische Plasmozytom, werden in Diagnose und Differenzialdiagnose nach den aktuellen pathogenetischen Kriterien dargestellt.

Literatur

  1. 1.
    International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757CrossRefGoogle Scholar
  2. 2.
    Aguilera NS, Kapadia SB, Nalesnik MA, Swerdlow SH (1995) Extramedullary plasmacytoma of the head and neck: use of paraffin sections to assess clonality with in situ hybridization, growth fraction, and the presence of Epstein-Barr virus. Mod Pathol 8:503–508PubMedPubMedCentralGoogle Scholar
  3. 3.
    Alexiou C, Kau RJ, Dietzfelbinger H et al (1999) Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85:2305–2314PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Avet-Loiseau H, Daviet A, Brigaudeau C et al (2001) Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 97:822–825PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R (2003) Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 101:1570–1571PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Avet-Loiseau H, Gerson F, Magrangeas F et al (2001) Rearrangements of the c-myc oncogene are present in 15 % of primary human multiple myeloma tumors. Blood 98:3082–3086PubMedCrossRefGoogle Scholar
  7. 7.
    Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80:2326–2335PubMedPubMedCentralGoogle Scholar
  8. 8.
    Bannas P, Kroger N, Adam G, Derlin T (2013) Modern imaging techniques in patients with multiple myeloma. Rofo 185:26–33PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Bardwick PA, Zvaifler NJ, Gill GN et al (1980) Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 59:311–322CrossRefGoogle Scholar
  10. 10.
    Bartl R, Frisch B, Burkhardt R et al (1982) Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol 51:361–375PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Bartl R, Frisch B, Fateh-Moghadam A et al (1987) Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 87:342–355PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Beck RC, Tubbs RR, Hussein M, Pettay J, Hsi ED (2003) Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma. Diagn Mol Pathol 12:14–20PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Berenson JR, Anderson KC, Audell RA et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28–38PubMedPubMedCentralGoogle Scholar
  14. 14.
    Bergsagel PL, Chesi M, Nardini E et al (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci Usa 93:13931–13936PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333–6338PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296–303PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Bink K, Haralambieva E, Kremer M et al (2008) Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica 93:623–626PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Blade J, Fernandez de Larrea C, Rosinol L et al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29:3805–3812PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Boll M, Parkins E, O’Connor SJ, Rawstron AC, Owen RG (2010) Extramedullary plasmacytoma are characterized by a ‘myeloma-like’ immunophenotype and genotype and occult bone marrow involvement. Br J Haematol 151:525–527PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Brouet JC, Fermand JP, Laurent G et al (1985) The association of chronic lymphocytic leukaemia and multiple myeloma: a study of eleven patients. Br J Haematol 59:55–66PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Brunning RD, McKenna RW (1994) Tumors of the bone marrow. AFIP, Washington D.C.Google Scholar
  22. 22.
    Chang ST, Liao YL, Lu CL, Chuang SS, Li CY (2007) Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol 128:339–344PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Chapman MA, Lawrence MS, Keats JJ et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471:467–472PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Chesi M, Nardini E, Brents LA et al (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260–264PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Chiecchio L, Dagrada GP, White HE et al (2009) Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 48:624–636PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Chng WJ, Huang GF, Chung TH et al (2011) Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25:1026–1035PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Colomo L, Loong F, Rives S et al (2004) Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 28:736–747PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M (2006) Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol 125:615–624PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Costes V, Magen V, Legouffe E et al (1999) The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 30:1405–1411PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Dao LN, Hanson CA, Dispenzieri A et al (2011) Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 117:6438–6444PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Delecluse HJ, Anagnostopoulos I, Dallenbach F et al (1997) Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89:1413–1420PubMedPubMedCentralGoogle Scholar
  32. 32.
    Dispenzieri A (2012) How I treat POEMS syndrome. Blood 119:5650–5658PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Dispenzieri A (2014) POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89:214–223PubMedCrossRefGoogle Scholar
  34. 34.
    Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Ely SA, Knowles DM (2002) Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 160:1293–1299PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Fend F (2010) Molekulare Pathologie von Plasmazellneoplasien. Pathologe 31(Suppl 2):188–192PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Fend F, Kremer M (2007) Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy. Pathobiology 74:133–143PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Fend F, Quintanilla-Martinez L (2013) B-Zellneoplasien mit plasmazellulärer und plasmablastischer Differenzierung. Pathologe 34:198–209PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Feyler S, O’Connor SJ, Rawstron AC et al (2008) IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol 140:547–551PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Fonseca R, Barlogie B, Bataille R et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546–1558PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Fonseca R, Bergsagel PL, Drach J et al (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23:2210–2221PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Fonseca R, Blood E, Rue M et al (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569–4575PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Gabrea A, Martelli ML, Qi Y et al (2008) Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer 47:573–590PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Galieni P, Cavo M, Pulsoni A et al (2000) Clinical outcome of extramedullary plasmacytoma. Haematologica 85:47–51PubMedPubMedCentralGoogle Scholar
  45. 45.
    Garcia-Sanz R, Orfao A, Gonzalez M et al (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93:1032–1037PubMedPubMedCentralGoogle Scholar
  46. 46.
    Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359–5366PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Greipp PR, Leong T, Bennett JM et al (1998) Plasmablastic morphology – an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 91:2501–2507PubMedPubMedCentralGoogle Scholar
  48. 48.
    Greipp PR, Raymond NM, Kyle RA, O’Fallon WM (1985) Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 65:305–310PubMedPubMedCentralGoogle Scholar
  49. 49.
    Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Grogan TM (2003) Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features. Semin Diagn Pathol 20:211–225PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Gualco G, Weiss LM, Bacchi CE (2010) MUM1/IRF4: A Review. Appl Immunohistochem Mol Morphol 18:301–310PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3–21PubMedPubMedCentralGoogle Scholar
  53. 53.
    Harrington AM, Hari P, Kroft SH (2009) Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol 132:60–66PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Heerema-McKenney A, Waldron J, Hughes S et al (2010) Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. Am J Clin Pathol 133:265–270PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104:607–618PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Hoyer JD, Hanson CA, Fonseca R et al (2000) The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 113:831–837PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Hsi ED, Lorsbach RB, Fend F, Dogan A (2011) Plasmablastic lymphoma and related disorders. Am J Clin Pathol 136:183–194PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Hussong JW, Perkins SL, Schnitzer B, Hargreaves H, Frizzera G (1999) Extramedullary plasmacytoma. A form of marginal zone cell lymphoma? Am J Clin Pathol 111:111–116PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Robert Koch Institut (2013) Krebs in Deutschland. Zentrum für Krebsregisterdaten, BerlinGoogle Scholar
  60. 60.
    Joshi R, Horncastle D, Elderfield K et al (2008) Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol 61:213–216PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Kaufmann H, Ackermann J, Baldia C et al (2004) Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 18:1879–1882PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Kremer M, Ott G, Nathrath M et al (2005) Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol 205:92–101PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Kremer M, Quintanilla-Martinez L, Nahrig J, von Schilling C, Fend F (2005) Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis. Virchows Arch 447:920–937PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Kuehl WM, Bergsagel PL (2012) Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 122:3456–3463PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Kyle RA, Durie BG, Rajkumar SV et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121–1127PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Kyle RA, Maldonado JE, Bayrd ED (1974) Plasma cell leukemia. Report on 17 cases. Arch Intern Med 133:813–818PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Kyle RA, Rajkumar SV (2006) Monoclonal gammopathy of undetermined significance. Br J Haematol 134:573–589PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Kyle RA, Rajkumar SV (2014) An overview of the progress in the treatment of multiple myeloma. Expert Rev Hematol 7:5–7PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Kyle RA, Therneau TM, Rajkumar SV et al (2004) Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 101:2667–2674PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Kyle RA, Therneau TM, Rajkumar SV et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Landgren O, Gridley G, Turesson I et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Landgren O, Kyle RA, Pfeiffer RM, et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–7PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Larson RS, Sukpanichnant S, Greer JP, Cousar JB, Collins RD (1997) The spectrum of multiple myeloma: diagnostic and biological implications. Hum Pathol 28:1336–1347PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Lin BT, Weiss LM (1997) Primary plasmacytoma of lymph nodes. Hum Pathol 28:1083–1090PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Lin P, Mahdavy M, Zhan F et al (2004) Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol 17:1217–1222PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Lohr JG, Stojanov P, Carter SL et al (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25:91–101PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Lorsbach RB, Hsi ED, Dogan A, Fend F (2011) Plasma cell myeloma and related neoplasms. Am J Clin Pathol 136:168–182PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S (2004) Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch 444:264–268PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Majumdar G, Grace RJ, Singh AK, Slater NG (1992) The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance. Leuk Lymphoma 8:491–493PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    McKenna RW, Kyle RA, Kuehl WM et al (2017) Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, al (Hrsg) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
  81. 81.
    Menke DM, Horny HP, Griesser H et al (2001) Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol 115:119–126PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Morgan GJ, Johnson DC (2014) Inherited genetic susceptibility to multiple myeloma. Leukemia 28:518–524PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335–348PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Ng AP, Wei A, Bhurani D et al (2006) The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 91:972–975PubMedPubMedCentralGoogle Scholar
  85. 85.
    Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM (2010) Plasma cell development and survival. Immunol Rev 237:140–159PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Paiva B, Almeida J, Perez-Andres M et al (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytom B Clin Cytom 78:239–252Google Scholar
  87. 87.
    Pantic M, Schroettner P, Pfeifer D et al (2010) Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma. Leukemia 24:885–890PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Pellat-Deceunynck C, Barille S, Jego G et al (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 12:1977–1982PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Perez-Persona E, Mateo G, Garcia-Sanz R et al (2010) Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 148:110–114PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Peterson LC, Brown BA, Crosson JT, Mladenovic J (1986) Application of the immunoperoxidase technic to bone marrow trephine biopsies in the classification of patients with monoclonal gammopathies. Am J Clin Pathol 85:688–693PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Petruzziello F, Zeppa P, Catalano L et al (2010) Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol 89:469–474PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Pileri S, Poggi S, Baglioni P et al (1989) Histology and immunohistology of bone marrow biopsy in multiple myeloma. Eur J Haematol 51(Suppl):52–59Google Scholar
  93. 93.
    Pruneri G, Fabris S, Balsini L et al (2000) Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 156:1505–1513PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Pruneri G, Ponzoni M, Ferreri AJ et al (2006) The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology 48:529–535PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–548PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Rajkumar SV, Dispenzieri A, Kyle RA (2006) Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 81:693–703PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Rajkumar SV, Fonseca R, Lacy MQ et al (1999) Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol 17:1551–1557PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Rajkumar SV, Kyle RA, Buadi FK (2010) Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 85:945–948PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Rasche L, Bernard C, Topp MS et al (2012) Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol 91:1031–1037PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Reichard K (2010) Plasma cell myeloma and other immunosecretory disorders. In: Foucar K, Reichart K, Czuchlewski D (Hrsg) Bone marrow pathology. ASCP Press, Chicago, S 524–553Google Scholar
  101. 101.
    Robillard N, Avet-Loiseau H, Garand R et al (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102:1070–1071PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Schmid C, Isaacson PG (1992) Bone marrow trephine biopsy in lymphoproliferative disease. J Clin Pathol 45:745–750PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Schmidt J, Federmann B, Schindler N et al (2015) MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol 169:795–803PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Seegmiller AC, Xu Y, McKenna RW, Karandikar NJ (2007) Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol 127:176–181PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Shao H, Xi L, Raffeld M et al (2010) Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression. Am J Surg Pathol 34:1425–1435PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Short KD, Rajkumar SV, Larson D et al (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25:906–908PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Siragusa S, Morice W, Gertz MA et al (2011) Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol 90:101–106PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Solly S (1844) Remarks on the pathology of mollities ossium with cases. Med Chir Trans Lond 27:435–461CrossRefGoogle Scholar
  109. 109.
    Specht K, Haralambieva E, Bink K et al (2004) Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104:1120–1126PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Susnerwala SS, Shanks JH, Banerjee SS et al (1997) Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer 75:921–927PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Takatsuki K, Sanada I (1983) Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 13:543–555PubMedPubMedCentralGoogle Scholar
  112. 112.
    Terpstra WE, Lokhorst HM, Blomjous F, Meuwissen OJ, Dekker AW (1992) Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol 82:46–49PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 367:826–833PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Van Camp B, Durie BG, Spier C et al (1990) Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 76:377–382PubMedPubMedCentralGoogle Scholar
  115. 115.
    Varettoni M, Zibellini S, Arcaini L et al (2013) MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 122:2284–2285PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Vasef MA, Medeiros LJ, Yospur LS et al (1997) Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 10:927–932PubMedPubMedCentralGoogle Scholar
  117. 117.
    Vega F, Chang CC, Medeiros LJ et al (2005) Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18:806–815PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Walker BA, Wardell CP, Johnson DC et al (2013) Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121:3413–3419PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418–5422PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108:2020–2202PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Institut für Pathologie und NeuropathologieEberhard-Karls-Universität TübingenTübingenDeutschland

Personalised recommendations